UY37463A - UNION PROTEINS - Google Patents

UNION PROTEINS

Info

Publication number
UY37463A
UY37463A UY0001037463A UY37463A UY37463A UY 37463 A UY37463 A UY 37463A UY 0001037463 A UY0001037463 A UY 0001037463A UY 37463 A UY37463 A UY 37463A UY 37463 A UY37463 A UY 37463A
Authority
UY
Uruguay
Prior art keywords
binding proteins
proteins
lag
relates
binding protein
Prior art date
Application number
UY0001037463A
Other languages
Spanish (es)
Inventor
David Favre
David Granger
Milloni Chhabra
Shari Gordon
Yuliya Demydchuk
Carolyn Enever
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of UY37463A publication Critical patent/UY37463A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una proteína de unión específica para al menos uno de los receptores PD-1 y LAG-3, que funcionan como puntos de control inmunológicos. En una realización, la invención también se refiere a una proteína de unión específica tanto para PD-1 como para LAG-3. La invención también proporciona métodos para preparar proteínas de unión, composiciones farmacéuticas que contienen las proteínas de unión y usos médicos de las proteínas de unión.The present invention relates to a specific binding protein for at least one of the PD-1 and LAG-3 receptors, which function as immunological control points. In one embodiment, the invention also relates to a specific binding protein for both PD-1 and LAG-3. The invention also provides methods for preparing binding proteins, pharmaceutical compositions containing the binding proteins and medical uses of the binding proteins.

UY0001037463A 2016-11-02 2017-10-31 UNION PROTEINS UY37463A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662416217P 2016-11-02 2016-11-02
US201662416218P 2016-11-02 2016-11-02
US201662416215P 2016-11-02 2016-11-02

Publications (1)

Publication Number Publication Date
UY37463A true UY37463A (en) 2018-05-31

Family

ID=60413144

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037463A UY37463A (en) 2016-11-02 2017-10-31 UNION PROTEINS

Country Status (3)

Country Link
TW (1) TW201829462A (en)
UY (1) UY37463A (en)
WO (1) WO2018083087A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019012076A (en) 2017-05-30 2019-12-09 Bristol Myers Squibb Co Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody.
CA3060989A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
EP4306542A3 (en) 2017-05-30 2024-04-17 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
US20210238287A1 (en) 2018-07-26 2021-08-05 Bristol-Myers Squibb Company LAG-3 Combination Therapy for the Treatment of Cancer
CN113286611A (en) 2018-10-19 2021-08-20 百时美施贵宝公司 Combination therapy for melanoma
EP3958900A4 (en) * 2019-04-26 2023-01-25 WuXi Biologics Ireland Limited Bispecific antibodies against pd-1 and lag-3
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
CN114174538A (en) 2019-05-30 2022-03-11 百时美施贵宝公司 Multiple tumor gene signatures suitable for immunooncology therapy
KR20220016155A (en) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 Methods of Identifying Suitable Subjects for Immuno-Oncology (I-O) Therapy
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
EP4031873A1 (en) 2019-09-22 2022-07-27 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
MX2022005474A (en) 2019-11-08 2022-06-02 Bristol Myers Squibb Co Lag-3 antagonist therapy for melanoma.
EP4100426A1 (en) 2020-02-06 2022-12-14 Bristol-Myers Squibb Company Il-10 and uses thereof
KR20220161395A (en) * 2020-04-01 2022-12-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Immunotheranotic Agents Targeting Mesenchymal Stem Cell-Derived Cancer Cells and Mesenchymal Stem Cell Associated Diseases
CN116234568A (en) 2020-07-07 2023-06-06 生物技术公司 Therapeutic RNAs for HPV-positive cancers
EP4204095A1 (en) 2020-08-28 2023-07-05 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
JP2023538955A (en) 2020-08-31 2023-09-12 ブリストル－マイヤーズ スクイブ カンパニー Cellular localization signatures and immunotherapy
KR20230093282A (en) 2020-10-23 2023-06-27 브리스톨-마이어스 스큅 컴퍼니 LAG-3 antagonist therapy for lung cancer
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
JP2024501029A (en) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Subcutaneous administration of PD1/PD-L1 antibodies
IL303648A (en) 2020-12-28 2023-08-01 Bristol Myers Squibb Co Antibody compositions and methods of use thereof
US20240181052A1 (en) 2021-03-29 2024-06-06 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
WO2022240741A1 (en) 2021-05-12 2022-11-17 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
KR20240046323A (en) 2021-07-13 2024-04-08 비온테크 에스이 Multispecific binding agent for CD40 and CD137 in combination therapy for cancer
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
CA3224890A1 (en) 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
WO2023147371A1 (en) 2022-01-26 2023-08-03 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
WO2023164638A1 (en) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024116140A1 (en) 2022-12-01 2024-06-06 Medimmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
JP3700859B2 (en) 1994-05-06 2005-09-28 アンスティテュ ギュスタブ ルシ Soluble polypeptide fraction of LAG-3 protein; production method, therapeutic preparation, anti-idiotype antibody
CN1533390A (en) 2001-03-19 2004-09-29 СҰҩƷ��ҵ��ʽ���� Drugs containing triazaspiro [5,5] undecane derivatives as the active ingredient
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc Agents that modulate immune cell activation and methods of use thereof
PT2206517T (en) 2002-07-03 2023-11-07 Tasuku Honjo Immunopotentiating compositions comprising anti-pd-l1 antibodies
ES2367430T3 (en) 2002-12-23 2011-11-03 Wyeth Llc ANTIBODIES AGAINST PD-1 AND ITS USES.
EP1641818B1 (en) 2003-07-04 2008-12-03 Affibody AB Polypeptides having binding affinity for her2
ES2427646T5 (en) 2005-05-09 2017-08-22 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies against programmed death 1 (PD1) and methods for the treatment of cancer through the use of anti-PD-1 antibodies alone or in combination with other immunotherapeutic agents
RS53072B (en) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
ES2614284T3 (en) * 2007-11-30 2017-05-30 Glaxo Group Limited Antigen binding constructs
PT2242773T (en) 2008-02-11 2017-09-15 Cure Tech Ltd Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
KR101001360B1 (en) 2008-06-16 2010-12-14 (주)기가레인 printed circuit board electrically connected to the ground of electronic device
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
US9181342B2 (en) 2008-09-12 2015-11-10 Isis Innovation Limited PD-1 specific antibodies and uses thereof
PL2342226T3 (en) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
JP2012518399A (en) * 2009-02-24 2012-08-16 グラクソ グループ リミテッド Antigen binding construct
CA2763491A1 (en) 2009-05-28 2010-12-02 Paul Andrew Hamblin Antigen-binding proteins
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
MX338353B (en) 2011-04-20 2016-04-13 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1.
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
CN106103484B (en) 2014-03-14 2021-08-20 诺华股份有限公司 Antibody molecules against LAG-3 and uses thereof
TWI693232B (en) * 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof

Also Published As

Publication number Publication date
WO2018083087A3 (en) 2018-11-29
TW201829462A (en) 2018-08-16
WO2018083087A2 (en) 2018-05-11

Similar Documents

Publication Publication Date Title
UY37463A (en) UNION PROTEINS
CO2018003973A2 (en) PD-1 binding proteins and methods for using them
CL2017001204A1 (en) 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
CO2018004743A2 (en) Anti-tigit antigen binding proteins and methods for using them
BR112018012707A2 (en) menin-mll interaction inhibitors
DOP2018000259A (en) BISPECIFIC UNION PROTEINS THAT JOIN AN IMMUNOMODULATORY PROTEIN AND A TUMORAL ANTIGEN
CL2019000261A1 (en) Modified polypeptides and uses thereof.
CL2018003136A1 (en) Specific binding proteins and uses thereof.
CO2018009995A2 (en) Binding proteins and methods of use thereof
BR112018000768A2 (en) anti-pd-1 antibodies, activatable anti-pd-1 antibodies and methods of use
MD3880654T2 (en) 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
EA202090931A3 (en) COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING WITH HYBRID PROTEINS
EA201890725A1 (en) PHARNESIDE X-RECEPTOR AGONISTS AND THEIR APPLICATION
UY35407A (en) ? FUSION PROTEINS UNDERSTANDING UNION PDGF and VEGF PORTIONS AND METHODS FOR USE ?.
SV2018005643A (en) QUICK INSULIN COMPOSITIONS ACTION
BR112015022191A2 (en) heteroaryl compounds, their use and composition comprising them
BR112016020368A2 (en) multimeric fc proteins
CO2019007846A2 (en) Anti-neuropilin antigen binding proteins and their methods of use
CR20170425A (en) NEW SPECIFIC PROTEINS FOR PIOVERDINA AND PIOQUELINA
CO2017002804A2 (en) Human derived dipeptide (dpr) anti-repeat antibody
BR112019000693A2 (en) mucocharge compositions and methods for use
CO2019006424A2 (en) Anti-gitr antigen binding proteins and methods of use thereof
EA201501028A1 (en) CONSTRUCTIONS OF MITOCHONDRIAL PROTEINS AND THEIR APPLICATION
CR20170020A (en) VARIANTS OF PROTEIN UNIONS TO FACTOR H AND METHODS OF USE OF THESE
BR112017028331A2 (en) fusion proteins that bind to human fc receptors